CELLINK has acquired the German-based biodispensing company dispendix for EUR 5m. Dispendix operates within the Life Science industry and focuses on biodispensing technology. Their technologies enable faster tests in drug development. Dispendix has one patented technology, I-DOT. Dispendix expects a net sales of SEK 16m in 2018, corresponding to a pro-forma EV/Sales multiple of 3.2x.